Effects of a pharmaceutical care intervention on clinical outcomes and patient adherence in coronary heart disease: the MIMeRiC randomized controlled trial

BMC Cardiovascular Disorders

Tommy Eriksson¹  Göran Petersson²  Malin Johansson Östbring³  Lina Hellström³ 

[1] Department of Biomedical Science, and Biofilm – Research Center for Biointerfaces, Malmö University, Malmö, Sweden;eHealth Institute, Department of Medicine and Optometry, Linnaeus University, Kalmar, Sweden;eHealth Institute, Department of Medicine and Optometry, Linnaeus University, Kalmar, Sweden;Pharmaceutical Department, Region Kalmar County, Building 2, floor 2, County Council Hospital, 391 85, Kalmar, Sweden;

关键词: Pharmaceutical care;    Medication adherence;    Medicine management;    Medication review;    Motivational interviewing;    Coronary heart disease;    Secondary prevention;    Low-density lipoprotein cholesterol;    Randomized controlled trial;   

DOI  :  10.1186/s12872-021-02178-0

来源: Springer

【 摘 要 】

BackgroundIn the treatment of coronary heart disease, secondary prevention goals are still often unmet and poor adherence to prescribed drugs has been suggested as one of the reasons. We aimed to investigate whether pharmaceutical care by a pharmacist at the cardiology clinic trained in motivational interviewing improves clinical outcomes and patient adherence.MethodsThis was a prospective, randomized, controlled, outcomes-blinded trial designed to compare pharmaceutical care follow-up with standard care. After standard follow-up at the cardiology clinic, patients in the intervention group were seen by a clinical pharmacist two to five times as required over seven months. Pharmacists were trained to use motivational interviewing in the consultations and they tailored their support to each patient’s clinical needs and beliefs about medicines. The primary study end-point was the proportion of patients who reached the treatment goal for low-density lipoprotein cholesterol by 12 months after discharge. The key secondary outcome was patient adherence to lipid-lowering therapy at 15 months after discharge, and other secondary outcomes were the effects on patient adherence to other preventive drugs, systolic blood pressure, disease-specific quality of life, and healthcare use.Results316 patients were included. The proportion of patients who reached the target for low-density lipoprotein cholesterol were 37.0% in the intervention group and 44.2% in the control group (P = .263). More intervention than control patients were adherent to cholesterol-lowering drugs (88 vs 77%; P = .033) and aspirin (97 vs 91%; P = .036) but not to beta-blocking agents or renin–angiotensin–aldosterone system inhibitors.ConclusionsOur intervention had no positive effects on risk factors for CHD, but it increased patient adherence. Further investigation of the intervention process is needed to explore the difference in results between patient adherence and medication effects. Longer follow-up of healthcare use and mortality will determine if the increased adherence per se eventually will have a meaningful effect on patient health.Trial registration: ClinicalTrials.gov NCT02102503, 03/04/2014 retrospectively registered.

【 授权许可】

CC BY